Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein-activated inward rectifier potassium (GIRK) channels, also known as Kir3 channels, are a family of inwardly rectifying potassium channels that serve as critical effectors for various G protein-coupled receptors (GPCRs). These channels are directly activated by the Gβγ subunits of Gi/o proteins, allowing potassium ions to flow out of the cell and causing membrane hyperpolarization, which inhibits cellular activity [1][2]. In the cardiovascular system, GIRK1/GIRK4 heteromers (IKACh) are activated by acetylcholine to slow the heart rate, and their overactivity is linked to atrial fibrillation [3]. In the brain, GIRK channels (comprising GIRK1, GIRK2, and GIRK3) mediate the inhibitory effects of neurotransmitters like GABA, dopamine, and opioids, playing roles in pain modulation, reward pathways, and seizure prevention [1][4]. Mutations in the KCNJ5 gene (GIRK4) are a well-documented cause of primary aldosteronism and secondary hypertension due to loss of channel selectivity and subsequent sodium influx in the adrenal cortex [5]. Therapeutic strategies currently focus on developing selective GIRK inhibitors for treating cardiac arrhythmias and primary aldosteronism, as well as modulators for neurological and psychiatric disorders [2][4]. Sources: [1] Lüscher, C., & Slesinger, P. A. (2010). "Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease." Nature Reviews Neuroscience. [2] Hibino, H., et al. (2010). "Inwardly Rectifying Potassium Channels: Their Structure, Function, and Physiological Roles." Physiological Reviews. [3] Ehrlich, J. R. (2008). "Inward rectifier potassium channels as a target for antiarrhythmic drug development." Current Opinion in Drug Discovery & Development. [4] Rifkin, R. A., et al. (2017). "G protein-gated inwardly rectifying potassium (GIRK) channels: A potential target for the treatment of chronic pain." Channels. [5] Choi, M., et al. (2011). "K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension." Science.
Direct activation by the G-beta-gamma (Gβγ) subunits of heterotrimeric G proteins following the stimulation of G protein-coupled receptors (GPCRs), leading to potassium efflux and cellular hyperpolarization; pharmacological agents may either block these channels to increase excitability (e.g., in cardiac arrhythmia) or modulate them to restore normal signaling.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-activated inward rectifier potassium channel (GIRK).